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Introduction: Identification of yeast isolated from clinical specimens to the species level has become
increasingly important. Ever-increasing numbers of immuno-suppressed patients, a widening range of
recognized pathogens, and the discovery of resistance to antifungal drugs are contributing factors to this
necessity.
Material and methods: A total of 487 yeast strains were studied for the primary isolation and presumptive
identification, directly from clinical specimen. Efficacy of CHROMagar Candida has been evaluated with
conventional methods including morphology on Corn mealtween 80 agar and biochemical methods by using
API 20 C AUX.
Results: The result of this study shows that CHROMagar Candida can easily identify three species of
Candida on the basis of colonial color and morphology, and accurately differentiate between them i.e.
Candida albicans, Candida tropicalis, and Candida krusei. The specificity and sensitivity of CHROMagar
Candida for C. albicans calculated as 99%, for C. tropicalis calculated as 98%, and C. krusei it is 100%.
Conclusion: The data presented supports the use of CHROMagar Candida for the rapid identification of
Candida species directly from clinical specimens in resource-limited settings, which could be very helpful in
developing appropriate therapeutic strategy and management of patients.
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I
nfections due to Candida species and other fungi have
increased dramatically in recent years and are of
particular importance because of the rising numberof
immuno-compromised patients (1). Although Candida
albicans remains the most common cause of human
Candidiasis, the frequency of infection attributed to other
members of the genus is also increasing (2, 3). This is
primarily due to the increase in the number of at risk
individuals, particularly those with impaired immunity,
such as transplant recipients, cancer patients receiving
chemotherapy, and human immunodeficiency virus-in-
fected patients (48). In the 1980s C. albicans accounted
for more than 80% of all candidal isolates recovered from
nosocomial yeast infection (9). Now, C. albicans accounts
for morethan80%ofallCandidabloodisolatesinarecent
review (10). The emergence of Candida species other than
C. albicans is a matter of concern in several major
institutions (3, 1114). These species are also shown to
have reduced susceptibility to antifungal agents. The
frequency of isolation of Candida krusei, Candida glab-
rata, Candida tropicalis, and Candida prapsilosis is steadily
increasing globally (15, 16). Fungal infections caused by
Candida species are being detected more frequently in
clinicallaboratories (17).ChangingCandida epidemiology
and availability of newer antifungal drugs with different
antifungal spectra means that physicians can no longer
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of fungi as yeast and mold (18). The conventional methods
of yeast identification, which mainly consist of assimilation
andfermentationcharacteristics,arereportedtobecumber-
some and beyond the expertise range available in local
laboratories. In non-specialized clinical laboratories (19),
especially in resource-limited settings, identification of yeast
and yeast-like organisms requires evaluation of microscopic
morphology and biochemical studies. Some unusual yeasts
may require unique morphological and biochemical studies
for identification, occasionally requiring up to 21 days of
incubation (20). Effective treatment requires both early
diagnosis and prompt initiation of therapy against fungal
infection (21). As the traditional methods are tedious and
time consuming to perform in the routine laboratories,
numerous isolation media are available in the market that
can identify pathogens within 472 hours, depending upon
the system (2226). Several brands of chromogenic media
are available for rapid identification of yeast. These special
media yield microbial colonies with varying pigmentation
secondary substrates that react with enzymes secreted by
micro organisms (27). These media are species-specific,
allowing the organisms to be identified to the species level
by their color and colonial characteristics. The manufac-
turer of CHROMagar Candida currently advertises
its product as able to detect and differentiate three species,
C. albicans by growth as light to medium green colonies,
C. tropicalis by growth as steel blue colonies accompanied
by purple pigmentation diffused into surrounding agar, and
C. krusei by growth as large, fuzzy, rose colored colonies
with white edges, after incubation for 48 hours at 378C, as
also reported in several studies (2832). Detection of
Candida on CHROMagar Candida from poly fungal speci-
m e na l s oa l l o w sd i r e c ta n dm o r er a p i da n ds p e c i f i c
identification of C. albicans and other spp. (29, 32, 33),
which could decrease the time required to obtain results.
Use of chromogenic media in clinical microbiology labora-
tories for the isolation and presumptive identification
of important Candida s p e c i e si se a s yt op e r f o r m ,r e q u i r e s
less time and is cost effective too. In this study our goal was
to evaluate the usefulness of CHROMagar Candida for
detection and identification of major Candida species with
accuracy to reduce the time of identification, and its
characterization from poly fungal specimens, especially in
developing countries in resource-limited settings.
Material and methods
Period of study
From April 2006 to September 2009.
Clinical isolates
A total of 487 yeast strains, including C. albicans (n
201), C. tropicalis (n140), C. prapsilosis (n32), C.
krusei (n30), C. glabrata (n21), Candida lusitaniae
(n21), Candida guilliermondii (n21), and Candida
famata (n21), were isolated from various clinical
specimens (n435) after direct plating on CHROMagar
Candida (109 urine, 11 blood, 81 sputum, 22 wound, 91
vaginal secretion, and 21 peritoneal fluid).
Strains and media
Quality control strains of C. albicans (ATCC90029), C.
prapsilosis (ATCC 2201), and C. krusei (ATCC6258) were
taken from ATCC (American type culture collection) and
IIDRL Laboratory, Department of Microbiology, Uni-
versity of Karachi, Pakistan. These control strains were
first confirmed by using conventional methods, including
germ tube formation test, and morphological character-
ization, which includes macroscopic features (morphol-
ogy, color, size, and texture) on Sabouraud dextrose agar
(SDA), Corn meal agar with tween 80 and CHROMagar
Candida (CHROMagar Candida, France).
CHROMagar Candida medium comprised per liter
peptone (10 g), glucose (20 g), agar (15 g), chloramphe-
nicol (0.5 g), and Chromogenic ix. (2 g), pH 6.1. This
medium was prepared according to the manufacturer’s
instructions, does not require autoclaving and is dis-
pensed into Petri plates after cooling. Culture was
inoculated and incubation was done at 378C. The
appearance of colonies, including color, size, and textures
on CHROMagar Candida, was analyzed.
Identification methods
All samples were first plated on SDA and CHROMagar
for 48 hours at 378C. The production of color and
morphology as described by the manufacturer were
recorded and the photographs were recorded. For C.
albicans the germ tube test was also performed to
differentiate between C. albicans and non albicans
Candida (NAC). The colonies from CHROMagar and
SDA were plated on corn meal agar with Tween 80 for
morphological examination of the production of chla-
mydospores, blastospores, true hyphae, and branched
pseudohyphae. The results were again compared with the
colonies that were grown on CHROMagar. These
colonies from SDA were subjected to biochemical
analysis by API 20C Aux (Biomuriex). Finally the
results were again compared with the culture results
and speciation was done. The data suggested that species
which were identified by CHROMagar and Corn meal
Tween 80 agar were the same as were confirmed by API
20C Aux. It means that in the presence of CHROMagar
it is not necessary to perform germ tube test for C.
albicans to confirm, as was also reported by Odds and
Bernaerts (31).
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We evaluated 487 yeast isolates from 435 clinical speci-
mens during April 2006 to September 2009 (Table 1).
These samples were directly plated on CHROMagar
Candida (CHROMagar Candida, France), SDA (Oxoid),
Corn meal agar (Oxoid) with Tween 80, and on CHRO-
Magar Candida and SDA. Colony growth was observed
after 24 and 48 hours of incubation. The development of
thecolonycolorwasnotedonCHROMagarCandida,and
we observed that the medium better differentiated the
color of colonies after 48 hours of incubation, while after
72hours ofincubationa distinctdeep colorof thecolonies
was observed. It was also noted that colony colors of
isolated strains were deepened with the passage of time
and persistence of pigment was also observed on CHRO-
Magar plates after more than 15 days, as also reported by
Pfaller, Houston and Coffmann (32).
The yeast cellswere identified according to morphology
and color of colonies on CHROMagar Candida. Germ
tube formation for C. albicans was done with microscopic
morphology on Corn mealTween 80 agar and confirmed
by API 20C Aux yeast identification panel (Biomuriex,
France), based on assimilation of carbohydrates.
The color of colonies on CHROMagar Candida was
similar as given by the manufacturer, i.e. green colonies of
C. albicans as indicated in Fig. 1C and D, steel blue
colonies of C. tropicalis (Fig. 1A and B) accompanied by
purple pigmentation which diffuses into surrounding agar
by growth, and large, fuzzy, rose colored colonies with
white edges of C. krusei, slightly white pale pink edges
and small pink to purple colonies of C. guilliermondii, can
easily be differentiated from Candida norvegensis which
also produces purple color colonies. The edges of all
colored colonies were paler and dark centered and the
colony size was between 1 and 5 mm in diameter, also
described by Odds and Bernaerts (31). The smooth white
to light pink colonies of C. glabrata which later became
pink (Fig. 1) and others spp. of Candida appear off-white,
including C. lusitaniae, C. famata, C. prapsilosis, and
Candida rugosa.
Comparative specificity and sensitivity of CHROMa-
gar Candida (CHROMagar Candida, France) in terms of
colony growth showed maximum sensitivity and specifi-
city with 95% confidence level in the range of 95.3100%
(Table 2).
CHROMagar Candida correctly identified 99% of C.
albicans, 98% C. tropicalis, 100% C. krusei, 94% of C.
glabrata but for other Candida species other tools of
identification, for example, API 20C Aux along with
CHROMagar Candida (CHROMagar Candida, France)
should be used for the correct identification. For
example, conventional methods, which include macro-
scopic/microscopic characteristic, and biochemical pro-
file by API system of identification (gold standard) to
facilitate the diagnosis with efficiency and accuracy,
should be possible simultaneously, so that the identifica-
tion should be accomplished.
Discussion
In resource-limited countries, lack of training and of
proper reagents, supplies and equipment makes detection
and rapid presumptive identification of yeast species
Table 1. Growth and colonial characteristics of 487 yeast isolates incubated for 2 days on CHROMagar Candida and Corn
mealtween 80 agar at 378C and identiﬁcation of clinical yeast isolates by API 20C Aux Candida kits (Biomerieux)
Species
Total number
of isolates
Colony characteristics
on CHROMagar Candida
Morphologic features on
Corn mealtween 80 agar
Identification by
API 20C AUX
Candida albicans 201 Apple green colonies; consistent Chlamydospores present; abundant
pseudohyphae, and true hyphae,
clusters of blastospores are present
Identified as C. albicans
Candida tropicalis 140 Dull blue, to purple color that
diffused into surrounding agar
with pale pink edges
Abundant pseudohyphae with
blastoconidia
Identified as C. tropicalis
Candida parapsilosis 32 White to pale pink colonies Clusters of blastospores were seen
occasionally giant cells
Identified as C.
parapsilosis
Candida krusei 30 Large, flat, spreading, pale pink
colonies with matt surfaces
Branched pseudo mycelium with
clusters and chains of blastospores
Identified as C. krusei
Candida glabrata 21 White large glossy pale pink to
violet colonies
Pseudohyphae not present Three isolates were not
C. glabrata
Candida
guilliermondii
21 Small pink to purple colonies Pseudohyphae with clusters of
blastospores
Identified as C. guillier-
mondii
Candida lusitaniae 21 Pink gray purple Branched pseudohyphae present Identified as C. lusitaniae
Candida famata 21 White to light pink colonies Pseudohyphae not present Identified as C. famata
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the poor patients, these laboratories do not go beyond the
germ tube test and limit their diagnosis to C. albicans or
NAC. The biochemical assimilation and fermentation
tests are not used in these laboratories due to lack of
resources, expertise, and the time required for these tests,
which increases the cost of mycology cultures (32). As a
result, direct selection of appropriate agents for antifun-
gal therapy or prophylaxis becomes almost impossible.
In resource-limited countries, clinicians have little
confidence in the accuracy and quality of laboratory
test results. They continue to prescribe costly antifungals
without knowing the exact antifungal profile of the
infectious agent; thereby they increase the economic
burden of the society, which also contributes to the
emergence of resistant Candida spp.
Without diagnostic tools, safe and effective drug
treatment, prevention of resistance to antimicrobial
therapy, and monitoring of resistance are not possible.
In this setting there is always a need of a medium which
helps not only in the isolation but also in the identifica-
tion of the agent at the species level. The CHROMagar
Candida medium was selected as a primary culture
medium along with SDA, and we found it an appropriate
and affordable diagnostics medium in a resource-limiting
setting. The reason is that an approximate cost per
culture for complete identification of Candida using
SDA, Corn meal agar, and API 20C Aux in Pakistan is
around US$ 15 (Pak Rs. 1,200), while CHROMagar
Candida costs around US$ 3 (Pak Rs. 250) per specimen
culture, and thus it is more economical.
We also found that CHROMagar Candida, France
easily identifies several species of Candida on the basis of
colony color and morphology and accurately differenti-
ates between the three most common species of Candida,
i.e. C. albicans, C. tropicalis, and C. krusei, which has also
been reported by Murray et al. (20). This medium easily
facilitates the detection of more than two species in a
single specimen by giving different colored colonies on a
plate at the same time, and it was also observed that if the
Fig. 1. (A) Candida tropicalis bluish purple colonies. (B) The appearance of C. tropicalis after 72 hours of incubation on
CHROMagar at 378C. (C) Apple green color colonies of Candida albicans grown for 48 hours on CHROMagar Candida at
378C. (D) Isolated green color colonies of C. albicans grown for 48 hours on CHROMagar Candida at 378C. (E) Direct plating
of sample on CHROMagar Candida for 48 hours at 378C. Mix colonies of different species can also seen on this plate. (F)
Smooth pink colonies of Candida glabrata grown for 48 hours on CHROMagar Candida at 378C.
Table 2. Comparative speciﬁcity and sensitivity of three different cultural media for Candida spp.
Name of media Specificity (N487) Sensitivity (N487) 95% Confidence level P-value
SDA 464 (95.3%) 467 (95.9%) 94.5100% B0.05
CHROMagar Candida 479 (98.4%) 478 (98.2%) 95.3100% B0.05
Corn meal agar with tween 80 470 (96.5%) 463 (95.0%) 9299.4% B0.05
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differentiate between mixtures of yeast species on a
single agar plate because of the different color reactions
(Fig. 1).
The specificity and sensitivity of CHROMagar Can-
dida for green color colony of C. albicans was calculated
as 99%, for blue colonies with dark center surrounded by
gray halo of C. tropicalis calculated as 98%, and for pink
rough and spreading colonies with broad white edges of
C. krusei as 100%. The CHROMagar Candida (CHRO-
Magar Candida, France) can be used as culture medium
for the primary isolation and presumptive identification
of organisms in cases where early diagnosis of infections
is needed without doing PCR (31). CHROMagar Can-
dida (CHROMagar Candida, France) can also support
the growth of fungi, in some cases where the causative
agent might be a mold, as reported by Beck-Sague and
Jarvis (9). This has also been observed in our study.
Sometimes we found a mixture of yeast and mold in a
single specimen, so this ability of the medium to support
the growth of mold can easily be utilized in the laboratory
setting.
Conclusion
On the whole it was observed that as the CHROMagar
Candida (CHROMagar Candida, France) gives a pre-
sumptive identification within 48 hours, preliminary
antifungal treatment can be administered with confidence
while the confirmed identification is being obtained. In
resource-limited settings, availability of this type of media
not only facilitates the provision of rapid patient care, but
may also assist to control the rise in antifungal agent
resistance by reducing the time taken for presumptive
identification of the organism at species level to start the
therapeutic regime.
We can conclude that use of fast and accurate
diagnostic methods can help in rapid treatment of
patients.
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